STEM-PD announces first in-human clinical trial results for Parkinson's disease cell therapy
Peer-Reviewed Publication
This month, we’re spotlighting Parkinson’s disease research in recognition of Parkinson’s Awareness Month. Here, we’ll share the latest research on Parkinson’s disease, how scientists are working to better understand its causes and progression, advances in treatment and care, and more.
Updates every hour. Last Updated: 20-Oct-2026 22:16 ET (21-Oct-2026 02:16 GMT/UTC)
A landmark study led from Lund, Sweden, has shown that transplanting stem-cell derived dopamine progenitor cells into the brain is feasible. Eight patients were transplanted in the first clinical trial, and no serious side effects linked to the transplanted cells were seen during the first year of follow‑up. The results are published in Nature Medicine.
Long-term exposure to certain types of air pollution is linked to an increased risk of Parkinson’s disease, Cambridge researchers have found in a critical review of the existing evidence.
New study from University Hospitals, Case Western Reserve University, and the Cleveland VA identifies a potential new treatment strategy for Parkinson's disease.
Scientists found that blocking the enzyme 15-PGDH protected brain cells and improved outcomes in multiple preclinical models of Parkinson's disease.
The findings suggest that drugs already being developed for other uses could potentially also be used to treat Parkinson's disease and other neurodegenerative conditions.
Parkinson’s disease (PD) is the second-most common neurodegenerative disorder, heavily characterized by the degenerative loss of dopaminergic neurons in the nigrostriatal pathway and neuroinflammation. While the prevalence of PD exhibits significant sex differences—occurring more frequently in men, though women often experience more severe advanced symptoms—the underlying molecular mechanisms driving these differences remain poorly understood. Furthermore, interleukin-6 (IL-6) has been increasingly linked to PD, yet its dual nature as both a pro-inflammatory and neuroprotective cytokine has sparked considerable controversy.
Scientists usually use animal models when studying Parkinson’s disease because these models mimic the disease well. They are limited, however, because they require either gene modifications or the injection of toxicants, which may not accurately represent how the disease occurs in humans.
But now, researchers at Texas A&M University have developed a model that uses a nontoxic way to generate the symptoms of Parkinson’s: infection with a virus called Theiler’s murine encephalomyelitis virus (TMEV), a natural pathogen in mice.
Their study is a game changer because it proves that a simple viral infection can trigger the exact brain damage and physical disabilities in animal models that are seen in people with Parkinson’s disease — and it sets the stage for additional studies.